Russia to work with GL Rapha to produce Sputnik V

13 November 2020

Russia has agreed terms for South Korean biotech GL Rapha to produce 150 million doses per year of its home-grown coronavirus vaccine, Sputnik V.

The Russian Direct Investment Fund (RDIF), the country’s sovereign wealth fund, has arranged for production to begin in December 2020, with a view towards supplying the vaccine from January 2021.

Sputnik V has been developed by the Moscow-based Gamaleya Research Institute of Epidemiology and Microbiology, drawing from years of experience working on vaccines for Middle East respiratory syndrome (MERS) and for the Ebola virus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK